KRAS degradation induces rapid lung cancer regression in preclinical mouse models

by Institute for Research in Biomedicine (IRB Barcelona)

edited by Stephanie Baum, reviewed by Andrew Zinin

Stephanie Baum

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

KRAS is one of the oncogenes most frequently altered in cancer, mutating in approximately one-third of lung adenocarcinomas. For decades, it was considered undruggable, until the recent approval of the first inhibitors against specific KRAS mutants. However, these treatments often lose efficacy over time due to the emergence of resistance. Now, a new study explores a different pharmacological strategy based on inducing tumor cells to degrade mutant KRAS themselves.

The study, led by IRB Barcelona and the Centro de Investigación del Cáncer (CSIC, USAL, FICUS), demonstrates that destroying the mutant KRAS protein, rather than merely blocking its activity, induces greater lung cancer regression in preclinical mouse models.

Published in Cancer Research, the study also provides one of the first in vivo characterizations of how tumors develop resistance to targeted protein degradation therapies based on PROTACs, a new modality of drugs which has already reached clinical approval.

"KRAS inhibitors have brought about a massive shift in the treatment of certain cancers, but resistance remains a major hurdle. We are now entering a new era where we can not only inhibit KRAS but also induce its degradation within cancer cells. Sequentially or even concurrently combining both pharmacological strategies could make a significant difference," explains Dr. Cristina Mayor-Ruiz, researcher at IRB Barcelona and co-lead author of the study.

Inducing tumor cells to degrade KRAS

Unlike classic inhibitors that block a protein's activity, targeted protein degradation strategies utilize molecules known as PROTACs to make the cell destroy the tumor protein itself.

Since PROTACs capable of directly degrading the KRAS^G12V mutation are currently unavailable, the researchers devised an ingenious strategy: They added a molecular tag to the protein. This allowed them to force its degradation using novel PROTACs—designed and synthesized at IRB Barcelona in collaboration with Antoni Riera's group—that specifically engage this tag.

Using this approach, the researchers successfully degraded KRAS^G12V in vivo, observing a pronounced tumor regression. This newly developed model has not only proven useful for studying lung cancer, but also provides a framework for investigating targeted protein degradation therapies against other cancer-relevant proteins and tumor types.

"What we observe is that lung cancer cells are extremely dependent on mutant KRAS. When we degrade the mutated protein, they stop proliferating and undergo apoptosis, even in the absence of a functional immune system," explains Dr. David Santamaría, researcher at the Centro de Investigación del Cáncer and co-lead author of the study.

Although treated tumors show increased immune cell infiltration, experiments conducted in immunodeficient mice demonstrated that the initial regression depends primarily on mechanisms intrinsic to the cancer cells rather than immune system activity.

The results further demonstrate that targeted KRAS^G12V degradation produces more profound and durable antitumor responses than those observed with conventional inhibitors.

Investigating resistance to degraders in vivo

One of the study's most significant findings is the detailed analysis of how resistance to targeted protein degradation therapies emerges in living tumors. The researchers observed that these resistance mechanisms are distinct from those previously described for traditional inhibitors.

Instead of mutating KRAS or reactivating classical oncogenic signaling pathways in response to the degraders, the cancer cells progressively alter the cellular machinery responsible for protein elimination, thereby preventing KRAS from being effectively degraded.

"It is a fundamentally distinct resistance mechanism. The tumor continues to rely on KRAS, but it essentially learns to sabotage the machinery meant to destroy it," points out Inés M. García-Pérez, co-first author of the study and Ph.D. researcher at IRB Barcelona.

Publication details

Targeted KRASG12V degradation in vivo elicits lung adenocarcinoma regression with subsequent relapse from dysregulated proteolysis, Cancer Research (2026).

Journal information: Cancer Research

Key medical concepts

KRAS protein, humanLung Cancer

Clinical categories

OncologyClinical pharmacology Provided by Institute for Research in Biomedicine (IRB Barcelona) Who's behind this story?

Stephanie Baum

Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: KRAS degradation induces rapid lung cancer regression in preclinical mouse models (2026, May 27) retrieved 27 May 2026 from https://medicalxpress.com/news/2026-05-kras-degradation-rapid-lung-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.